# Endo Tools Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/endo-tools-therapeutics-s-a

- Industry: Medical Devices & Equipment
- Headquarters: Belgium
- Website: www.endotools.be
- Total disclosed funding: $39M
- Latest round: Series C (Jul 16, 2026)
- Investors on record: 6

## About

Endo Tools Therapeutics S.A. is a medical device company specializing in innovative solutions for gastric conditions, particularly focusing on incisionless surgical techniques to enhance therapeutic interventions for obesity. Founded in 2008 in Belgium, Endo Tools Therapeutics S.A. develops advanced medical devices for endoscopic procedures. CEO Alexandre Chau leads the company. In July 2026, Endo Tools Therapeutics S.A. raised USD 23 million in series C funding led by Capricorn Partners, with participation from McPike Global Family Office.

Endo Tools Therapeutics (ETT) specializes in the development of advanced medical devices aimed at providing innovative therapeutic interventions for gastric conditions, particularly obesity. The company's core product is the endomina®, which incorporates a triangulation platform and a tissue piercing and approximation instrument known as TAPES. This device allows gastroenterologists to perform endoscopic suturing through a natural orifice—the mouth—thereby facilitating incisionless procedures that mimic laparoscopic interventions. The endomina® and TAPES are CE marked for endoscopic gastroplasty and have received FDA clearance for tissue approximation. ETT's products primarily serve healthcare providers in Europe, where the endomina® procedure has been successfully implemented in over 500 patients, enhancing treatment options for individuals with gastric conditions. ETT generates revenue through the sale of its specialized medical devices, particularly the endomina® and its associated instruments. The firm typically engages in business-to-business (B2B) transactions, supplying its products directly to hospitals and medical institutions specializing in gastroenterology. Transaction structures often involve bulk purchases or long-term contracts, allowing healthcare providers to access the necessary tools for performing incisionless surgeries. For the year 2023, ETT reported an EBITDA of EUR -4,451,463.20. Endo Tools Therapeutics S.A. aims to expand its product line and geographic reach, with the intent to introduce new devices designed for enhanced gastric treatments.

The company will use the July 2026 funding to advance commercialization of the endomina platform in the U.S., Europe and the Middle East, and generate clinical evidence to support a U.S. weight loss indication.

## Funding rounds

- Series C, Jul 16, 2026, $23M — Capricorn Partners, McPike Global Family Office
- Series D, Jan 29, 2021, $9.6M — SFPI-FPIM, Epimede, Chagral Invest, White Fund
- Series C, Oct 18, 2018, $5.9M — SFPI-FPIM, Epimede, Chagral Invest

## Investors

- SFPI-FPIM — Series C, Series D
- Epimede (https://capitalatlas.ai/funds/epimede) — Series C, Series D
- Chagral Invest — Series C, Series D
- White Fund (https://capitalatlas.ai/funds/white-fund) — Series D
- Capricorn Partners (https://capitalatlas.ai/funds/capricorn-partners) — Series C
- McPike Global Family Office — Series C